Pacira BioSciences (PCRX) Competitors $22.44 -0.20 (-0.88%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$22.44 +0.00 (+0.02%) As of 05/18/2026 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMBShould you buy Pacira BioSciences stock or one of its competitors? MarketBeat compares Pacira BioSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pacira BioSciences include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Perrigo (PRGO), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry. PCRX vs. SUPNPCRX vs. NKTRPCRX vs. PRGOPCRX vs. OMERPCRX vs. ASMBHow does Pacira BioSciences compare to Supernus Pharmaceuticals?Pacira BioSciences (NASDAQ:PCRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Do institutionals & insiders have more ownership in PCRX or SUPN? 99.7% of Pacira BioSciences shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is PCRX or SUPN more profitable? Pacira BioSciences has a net margin of 0.70% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Pacira BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Pacira BioSciences0.70% 10.24% 5.47% Supernus Pharmaceuticals -3.74%13.07%9.66% Do analysts recommend PCRX or SUPN? Pacira BioSciences presently has a consensus price target of $29.40, indicating a potential upside of 31.02%. Supernus Pharmaceuticals has a consensus price target of $62.17, indicating a potential upside of 28.63%. Given Pacira BioSciences' higher possible upside, equities analysts plainly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacira BioSciences 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29Supernus Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Does the media refer more to PCRX or SUPN? In the previous week, Pacira BioSciences had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 7 mentions for Pacira BioSciences and 4 mentions for Supernus Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.81 beat Supernus Pharmaceuticals' score of 0.53 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PCRX or SUPN? Pacira BioSciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Which has stronger earnings and valuation, PCRX or SUPN? Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacira BioSciences$726.41M1.22$7.03M$0.12187.00Supernus Pharmaceuticals$718.95M3.90-$38.55M-$0.51N/A SummaryPacira BioSciences beats Supernus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.How does Pacira BioSciences compare to Nektar Therapeutics?Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Is PCRX or NKTR more profitable? Pacira BioSciences has a net margin of 0.70% compared to Nektar Therapeutics' net margin of -284.18%. Pacira BioSciences' return on equity of 10.24% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pacira BioSciences0.70% 10.24% 5.47% Nektar Therapeutics -284.18%-85.40%-39.99% Do analysts prefer PCRX or NKTR? Pacira BioSciences currently has a consensus target price of $29.40, suggesting a potential upside of 31.02%. Nektar Therapeutics has a consensus target price of $149.63, suggesting a potential upside of 118.65%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacira BioSciences 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29Nektar Therapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Do insiders & institutionals hold more shares of PCRX or NKTR? 99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer PCRX or NKTR? In the previous week, Nektar Therapeutics had 9 more articles in the media than Pacira BioSciences. MarketBeat recorded 16 mentions for Nektar Therapeutics and 7 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.81 beat Nektar Therapeutics' score of 0.69 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has stronger valuation & earnings, PCRX or NKTR? Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacira BioSciences$726.41M1.22$7.03M$0.12187.00Nektar Therapeutics$55.23M41.87-$164.08M-$8.42N/A Which has more volatility & risk, PCRX or NKTR? Pacira BioSciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. SummaryPacira BioSciences beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.How does Pacira BioSciences compare to Perrigo?Pacira BioSciences (NASDAQ:PCRX) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Do analysts prefer PCRX or PRGO? Pacira BioSciences presently has a consensus price target of $29.40, indicating a potential upside of 31.02%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 80.77%. Given Perrigo's higher possible upside, analysts clearly believe Perrigo is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacira BioSciences 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29Perrigo 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better valuation & earnings, PCRX or PRGO? Pacira BioSciences has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacira BioSciences$726.41M1.22$7.03M$0.12187.00Perrigo$4.25B0.35-$1.43B-$13.10N/A Is PCRX or PRGO more profitable? Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Pacira BioSciences0.70% 10.24% 5.47% Perrigo -43.50%9.96%3.90% Do insiders and institutionals believe in PCRX or PRGO? 99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 0.4% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer PCRX or PRGO? In the previous week, Pacira BioSciences had 6 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Pacira BioSciences and 1 mentions for Perrigo. Perrigo's average media sentiment score of 0.84 beat Pacira BioSciences' score of 0.81 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, PCRX or PRGO? Pacira BioSciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. SummaryPacira BioSciences beats Perrigo on 12 of the 16 factors compared between the two stocks.How does Pacira BioSciences compare to Omeros?Pacira BioSciences (NASDAQ:PCRX) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Do analysts prefer PCRX or OMER? Pacira BioSciences presently has a consensus price target of $29.40, suggesting a potential upside of 31.02%. Omeros has a consensus price target of $40.33, suggesting a potential upside of 244.73%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacira BioSciences 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29Omeros 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has better valuation & earnings, PCRX or OMER? Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacira BioSciences$726.41M1.22$7.03M$0.12187.00OmerosN/AN/A-$3.35M$0.7016.71 Do insiders & institutionals hold more shares of PCRX or OMER? 99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is PCRX or OMER more profitable? Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.Company Net Margins Return on Equity Return on Assets Pacira BioSciences0.70% 10.24% 5.47% Omeros N/A -102.16%64.87% Which has more risk & volatility, PCRX or OMER? Pacira BioSciences has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Omeros has a beta of 2.66, indicating that its share price is 166% more volatile than the broader market. Does the media refer more to PCRX or OMER? In the previous week, Omeros had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 10 mentions for Omeros and 7 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.81 beat Omeros' score of 0.53 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPacira BioSciences and Omeros tied by winning 8 of the 16 factors compared between the two stocks.How does Pacira BioSciences compare to Assembly Biosciences?Assembly Biosciences (NASDAQ:ASMB) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Which has more volatility & risk, ASMB or PCRX? Assembly Biosciences has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Does the media favor ASMB or PCRX? In the previous week, Assembly Biosciences had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 10 mentions for Assembly Biosciences and 7 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.81 beat Assembly Biosciences' score of 0.39 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ASMB or PCRX? 19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate ASMB or PCRX? Assembly Biosciences presently has a consensus target price of $42.75, suggesting a potential upside of 55.91%. Pacira BioSciences has a consensus target price of $29.40, suggesting a potential upside of 31.02%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Pacira BioSciences 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Which has higher earnings & valuation, ASMB or PCRX? Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAssembly Biosciences$72.30M6.03-$6.12M-$0.11N/APacira BioSciences$726.41M1.22$7.03M$0.12187.00 Is ASMB or PCRX more profitable? Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Assembly Biosciences-8.98% -4.21% -3.14% Pacira BioSciences 0.70%10.24%5.47% SummaryPacira BioSciences beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks. Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCRX vs. The Competition ExportMetricPacira BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$890.84M$3.31B$6.25B$12.29BDividend YieldN/A2.34%2.80%5.30%P/E Ratio187.0218.1320.8625.23Price / Sales1.22275.96550.9175.54Price / Cash5.8755.2727.4837.30Price / Book1.396.579.676.63Net Income$7.03M$24.35M$3.56B$335.59M7 Day Performance-1.75%-2.53%-1.69%-1.20%1 Month Performance-9.22%-3.55%-2.65%-1.16%1 Year Performance-14.19%53.51%30.03%28.10% Pacira BioSciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCRXPacira BioSciences3.4326 of 5 stars$22.44-0.9%$29.40+31.0%-13.2%$890.84M$726.41M187.02720SUPNSupernus Pharmaceuticals3.1134 of 5 stars$49.37-4.2%$62.17+25.9%+44.6%$2.99B$718.95MN/A580NKTRNektar Therapeutics2.7806 of 5 stars$78.72-3.9%$149.63+90.1%+566.0%$2.76B$55.23MN/A220Analyst UpgradePRGOPerrigo4.4901 of 5 stars$11.07-5.5%$19.33+74.7%-60.4%$1.62B$4.25BN/A8,100OMEROmeros3.8538 of 5 stars$14.36+1.6%$40.33+180.9%+264.5%$1.02BN/AN/A210Earnings Report Related Companies and Tools Related Companies Supernus Pharmaceuticals Competitors Nektar Therapeutics Competitors Perrigo Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors AbbVie Competitors Merck & Co., Inc. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCRX) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
